SCHEMBL471934

SCHEMBL471934

Cc1cc(/C=C/C(=O)O)ccc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.70
HSD17B10 Q99714 3/20 0.70
CA12 O43570 3/20 0.70
CA1 P00915 3/20 0.70
CA2 P00918 3/20 0.70
CA3 P07451 3/20 0.70
CA4 P22748 3/20 0.70
CA6 P23280 3/20 0.70
CA5A P35218 3/20 0.70
CA7 P43166 3/20 0.70
CA9 Q16790 3/20 0.70
CA14 Q9ULX7 3/20 0.70
CA5B Q9Y2D0 3/20 0.70
AKR1B10 O60218 3/20 0.70
AKR1B1 P15121 3/20 0.70
DPP4 P27487 3/20 0.70
BACE1 P56817 2/20 0.70
ALDH1A1 P00352 2/20 0.70
HPGD P15428 2/20 0.70
MAPK1 P28482 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL471935 1.00 KDM4E (0.70) KDM4EHSD17B10CA12CA1CA2
SCHEMBL27524817 0.98 KDM4E (0.68) KDM4EHSD17B10CA12CA1CA2
SCHEMBL27524820 0.98 KDM4E (0.68) KDM4EHSD17B10CA12CA1CA2
SCHEMBL15481424 0.87 BACE1 (0.66) KDM4EHSD17B10CA12CA1CA2
SCHEMBL12220501 0.85 IAPP (0.73) KDM4EHSD17B10CA12CA1CA2
SCHEMBL14472602 0.85 KDM4E (0.70) KDM4EHSD17B10CA12CA1CA2
SCHEMBL584596 0.85 KDM4E (0.58) KDM4EHSD17B10CA12CA1CA2
SCHEMBL111230 0.85 KDM4E (0.58) KDM4EHSD17B10CA12CA1CA2
SCHEMBL8965107 0.84 BACE1 (0.88) KDM4EHSD17B10CA12CA1CA2
SCHEMBL8965104 0.84 BACE1 (0.88) KDM4EHSD17B10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119709577-A Recombinant strain for expressing phenolic acid decarboxylase as well as construction method and application thereof 南京工业大学 2025-03-28 CN disclosed
CN-116283817-B NO donor type HDAC inhibitor, composition and application thereof 安徽中医药大学 2024-08-02 CN disclosed
CN-118266572-A Application of 3-methoxyphenyl-2-acrylic compound as bitter taste inhibitor 华南理工大学 2024-07-02 CN disclosed
US-20230293458-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2023-09-21 US disclosed
CN-116574054-A Selective estrogen receptor down regulator compound, preparation method and application 南京中医药大学 2023-08-11 CN disclosed
CN-116283817-A NO donor type HDAC inhibitor, composition and application thereof 安徽中医药大学 2023-06-23 CN disclosed
US-20230127708-A1 GASIFIED SOLUTIONS WITH IMPROVED SENSORY PROPERTIES CARGILL, INCORPORATED (US) 2023-04-27 US disclosed
CN-111602087-B Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element, polymer and compound JSR株式会社 2023-03-24 CN disclosed
WO-2022138670-A1 COMPOUND, POLYMER, COMPOSITION, FILM-FORMING COMPOSITION, PATTERN FORMATION METHOD, METHOD FOR FORMING INSULATING FILMS, AND COMPOUND PRODUCTION METHOD 三菱瓦斯化学株式会社 2022-06-30 WO disclosed
CN-113880695-A Preparation method of 4-vinylphenol compound 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2022-01-04 CN disclosed
EP-2412701-A1 NOVEL AMIDE DERIVATIVE AND SKIN WHITENING AGENT Ajinomoto Co., Inc. (JP) 2012-02-01 EP disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
US-8034365-B2 Polymer substituted with amide or thioamide groups; vascular stents, bioreabsorbable polymers REVA MEDICAL, INC. (US) 2011-10-11 US disclosed
WO-2010022049-A1 THE DERIVATIVES OF 8-EPIBLECHNIC ACID AND THEIR EFFECTS ON DOWN-REGULATION OF ENDOTHELIN (ETA) RECEPTOR MRNA SCINOPHARM TAIWAN, LTD. (TW) 2010-02-25 WO disclosed
US-7473417-B2 Inherently radiopaque bioresorbable polymers for multiple uses REVA MEDICAL, INC. (US) 2009-01-06 US disclosed
US-20080112999-A1 N-SUBSTITUTED MONOMERS AND POLYMERS REVA MEDICAL, INC. (US) 2008-05-15 US disclosed
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293458-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME SI, FABP2, CEL KDM4E 2438/4885HSD17B10 1415/4885CA12 48/4885
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 KDM4E 2860/4885HSD17B10 2109/4885CA12 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.